|
Video: What is a Stock Split?
|
|
Replimune Group is a clinical-stage biotechnology company focused on applying its capabilities in the field of oncolytic immunotherapy to transform the lives of cancer patients through its tumor-directed oncolytic immunotherapies. Co.'s RPx product candidates in its development pipeline include: RP1, which is a selectively replicating version of herpes simplex virus 1 that expresses GALV-GP R(-) and human GM-CSF; RP2, which expresses an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which expresses immune-activating proteins that stimulate T cells, in addition to anti-CTLA-4 and GALV-GP R(-). According to our Replimune Group stock split history records, Replimune Group has had 0 splits. | |
|
Replimune Group (REPL) has 0 splits in our Replimune Group stock split history database.
Looking at the Replimune Group stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Replimune Group shares, starting with a $10,000 purchase of REPL, presented on a split-history-adjusted basis factoring in the complete Replimune Group stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
07/23/2018 |
|
End date: |
05/06/2024 |
|
Start price/share: |
$15.00 |
|
End price/share: |
$7.01 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-53.27% |
|
Average Annual Total Return: |
-12.31% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$4,672.82 |
|
Years: |
5.79 |
|
|
|
|
|